Literature DB >> 7988476

Subtype selectivity of peptide analogs for all five cloned human somatostatin receptors (hsstr 1-5).

Y C Patel1, C B Srikant.   

Abstract

Recent reports (Raynor et al) have claimed the identification of potent somatostatin (SST) agonists exhibiting binding affinities of 1-2 pM and up to 30,000 fold binding selectivity for several of the 5 cloned sstr subtypes. These conclusions, however, are based on binding comparisons of sstr subtypes from different species expressed in different cell lines and studied with different radioligands. To eliminate the effect of species and/or methodological variations, we have investigated agonist selectivity of 32 synthetic SST analogs for all 5 hsstrs stably expressed in CHO-K1 cells under identical binding conditions. We show that hsstr2, 3, 5 react potently with hexapeptide as well as cyclic and linear octapeptide analogs and belong to a similar sstr subclass. hsstr1 and 4 react poorly with these analogs and belong to a separate subclass. The present generation of SST analogs exhibit a modest-50 fold increase in binding potency compared to SST-14 for 2 subtypes (hsstr2, 3), and relative selectivity for only 1 subtype (hsstr2) which is at best only 35 fold. The potency and degree of selectivity of these analogs is several orders of magnitude less than that reported earlier and suggests the need for caution in using these compounds as putative superagonists or subtype selective compounds for any of the individual sstrs.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7988476     DOI: 10.1210/endo.135.6.7988476

Source DB:  PubMed          Journal:  Endocrinology        ISSN: 0013-7227            Impact factor:   4.736


  63 in total

Review 1.  The therapeutic value of somatostatin and its analogues.

Authors:  S Farooqi; J S Bevan; M C Sheppard; J A Wass
Journal:  Pituitary       Date:  1999-06       Impact factor: 4.107

2.  Somatostatin-induced regulation of SST(2A) receptor expression and cellsurface availability in central neurons: role of receptor internalization.

Authors:  H Boudin; P Sarret; J Mazella; A Schonbrunn; A Beaudet
Journal:  J Neurosci       Date:  2000-08-15       Impact factor: 6.167

3.  Dissociation between tumor shrinkage and hormonal response during somatostatin analog treatment in an acromegalic patient: preferential expression of somatostatin receptor subtype 3.

Authors:  A P Casarini; E M Pinto; R S Jallad; R R Giorgi; D Giannella-Neto; M D Bronstein
Journal:  J Endocrinol Invest       Date:  2006-10       Impact factor: 4.256

4.  Somatostatin octapeptides (lanreotide, octreotide, vapreotide, and their analogs) share the growth hormone-releasing peptide receptor in the human pituitary gland.

Authors:  R Deghenghi; M Papotti; E Ghigo; G Muccioli; V Locatelli
Journal:  Endocrine       Date:  2001-02       Impact factor: 3.633

5.  Occurrence of two somatostatin variants in the frog brain: characterization of the cDNAs, distribution of the mRNAs, and receptor-binding affinities of the peptides.

Authors:  H Tostivint; I Lihrmann; C Bucharles; D Vieau; Y Coulouarn; A Fournier; J M Conlon; H Vaudry
Journal:  Proc Natl Acad Sci U S A       Date:  1996-10-29       Impact factor: 11.205

6.  A selective somatostatin type-2 receptor agonist inhibits neointimal thickening and enhances endothelial cell growth and morphology following aortic balloon injury in the rabbit.

Authors:  Natalie K Schiller; Alvin M Timothy; Harmeet S Aurora; I-Li Chen; David H Coy; William A Murphy; Donald L Akers; Vivian A Fonseca; Philip J Kadowitz; Dennis B McNamara
Journal:  Mol Cell Biochem       Date:  2002-11       Impact factor: 3.396

7.  Potent antagonism by BIM-23056 at the human recombinant somatostatin sst5 receptor.

Authors:  G F Wilkinson; R J Thurlow; L A Sellers; J E Coote; W Feniuk; P P Humphrey
Journal:  Br J Pharmacol       Date:  1996-06       Impact factor: 8.739

8.  Somatostatin receptor subtype specificity in human fetal pituitary cultures. Differential role of SSTR2 and SSTR5 for growth hormone, thyroid-stimulating hormone, and prolactin regulation.

Authors:  I Shimon; J E Taylor; J Z Dong; R A Bitonte; S Kim; B Morgan; D H Coy; M D Culler; S Melmed
Journal:  J Clin Invest       Date:  1997-02-15       Impact factor: 14.808

9.  Inhibitory effect of octreotide on gastric cancer growth via MAPK pathway.

Authors:  Chun-Hui Wang; Cheng-Wei Tang; Chun-Lun Liu; Li-Ping Tang
Journal:  World J Gastroenterol       Date:  2003-09       Impact factor: 5.742

10.  Differences in the operational characteristics of the human recombinant somatostatin receptor types, sst1 and sst2, in mouse fibroblast (Ltk-) cells.

Authors:  S W Castro; G Buell; W Feniuk; P P Humphrey
Journal:  Br J Pharmacol       Date:  1996-02       Impact factor: 8.739

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.